Liposomal Irinotecan for Pancreatic Cancer: Is It Worth It?

Some oncologists have called the regimen a new standard of care, while others aren't convinced that the new first-line pancreatic cancer regimen is worth the high cost.

Related Keywords

New York , United States , Canada , Tennessee , Memorial Sloan Kettering Cancer Center , Utah , California , University Of Utah , Salt Lake City , Los Angeles , Christopher Booth , Christopher Nevala Plagemann , Laura Goff , Bishal Gyawali , Eileen Oreilly , Ignacio Garrido Laguna , Zeva Wainberg , Vanderbilt Ingram Cancer Center , Queen University , Drug Administration , University Of California , Medscape Medical ,